TRANSFUSION MEDICINE PROTOCOLS

Tetanus Immunoglobulin VF (For Intravenous Use)

This document should be read in conjunction with the Disclaimer

DESCRIPTION	**Intravenous Tetanus Immunoglobulin-VF (For Intravenous Use)**
SPECIFICATIONS	Each ampoule contains 4000 IU tetanus immunoglobulin for intravenous use. Manufactured from pooled human plasma. Tetanus Immunoglobulin-VF IV Product Detail (for Intravenous Use)
VIAL SIZE	4000 IU vial
INDICATIONS	Used in the management of clinical tetanus. Refer to Tetanus Immunoglobulin-VF IV Product Information The WNHS Infection Control Manual is available for reference
CONTRAINDICATIONS AND PRECAUTIONS	**Precautions** – products should be given only if benefits outweigh possible risks: • Patients who have had a true anaphylactic reaction to human immunoglobulin • Patients with isolated IgA deficiency who have antibody against IgA Refer to Tetanus Immunoglobulin-VF IV Product Information for more information.
CONSUMER INFORMATION	Tetanus Immunoglobulin-VF IV Consumer Medicine Information
CONSENT	Manufactured from pooled human plasma. Refer to Transfusion Medicine Protocol WNHS Blood Product Prescription, Informed Consent. And Refusal
DOSE	Seek advice from the Clinical Microbiologist or requesting Clinical Haematologist regarding dose. The recommended dose of Tetanus Immunoglobulin-VF (for Intravenous Use) for

	the treatment of tetanus is 4000 IU. It should be administered by slow intravenous infusion. After administration of this dose (4000 IU), it has been shown that circulating antibody levels are maintained above the minimum protective titre for at least 6 weeks. Refer to Tetanus Immunoglobulin-VF IV Product Information for more information.
ORDERING	Contact Transfusion Medicine Unit (TMU) and provide patient details and clinical history.
ADMINISTRATION	• Two staff to perform checks as per the Clinical Practice Manual, WNHS Pharmacy Medication Checking and Administration processes. Check Issue label and patient ID. Check right patient, right product, right dose – prescription matches product supplied. If not identical, contact TMU and prescribing doctor. • The product must be used immediately after opening. Any unused solution must be discarded. • Allow product to reach room temperature before administration. • Do not use the product if it appears turbid or cloudy. • **Tetanus Immunoglobulin-VF IV (for intravenous use) MUST NOT be administered intramuscularly.** • It is usual to gradually increase the infusion rate (provided the patient's vital signs are satisfactory at the lower rate) to the desired rate over the first 30 minutes. The infusion may be commenced at the rate of 1 mL per minute. After 15 minutes the rate may be gradually increased to a maximum of 3 to 4 mL per minute over a further 15 minutes.
OBSERVATIONS	Undertake observations as for all blood products. Vital signs (temperature, pulse, respiration, blood pressure) must be recorded on the observation chart in the medical record. Observe for signs of adverse reaction - Observe for signs of adverse reactions - see Tetanus Immunoglobulin-VF IV Product Information
ADVERSE REACTIONS	Reactions tend to be related to the infusion rate and are most likely to occur during the first hour of the infusion. For more information see Tetanus Immunoglobulin-VF IV Product Information Any adverse reaction should be reported to the Clinical Haematologist/Microbiologist and TMU. Any adverse reaction should be reported to the Clinical Microbiologist/ Haematologist and TMU. Refer to WNHS Management of Transfusion Reactions and Adverse Events,

DOCUMENTATION	A record should be kept in the patient's history of the following: • The date and time of infusion • Patients observations and condition during the infusion • Amount given • The batch number and expiry date of each bottle used (place a sticker with the batch number on the Transfusion Medicine Record sheet MR735). This information is important should the patient have a reaction to the infusion or if there is a need to trace recipients of certain batch numbers at a later date.
For further information, refer to product insert Return product to TMU immediately if no longer required. Product should be used for intended patient (issue label) only.	

References

- Australian Government Department of Health, The Australian Immunisation Handbook, 10th Edition, 2013
- Tetanus Immunoglobulin-VF IV Product Detail (for Intravenous Use)
- CSL Global Tetanus Immunoglobulin-VF IV
- CSL Tetanus Immunoglobulin-VF IV Product Information
- CSL Website and Product Information http://www.csl.com.au/products
- Australian Red Cross Blood Service – Blood products and transfusion practice for health professionals. http://www.transfusion.com.au/blood_products/fractionated_plasma/immunoglobulins
- The Australian Blood Service (ARCBS) Blood Component Information http://www.transfusion.com.au/sites/default/files/BCI%202009.pdf
- Flippin' Blood BloodSafe SA / ARCBS Second Edition June 2012 http://resources.transfusion.com.au/cdm/ref/collection/p16691coll1/id/20
- National Safety and Quality Health Service Standards, October 2012. Standard 7: Blood and Blood Products

Related WNHS policies, procedures and guidelines

- WNHS Blood Product Prescription, Consent and Refusal
- WNHS Management of Transfusion Reactions and Adverse Events
- WNHS Pharmacy Medication Checking and Administration
- Neonatology Clinical Care Guidelines
- Obstetrics and Gynaecology Clinical Guidelines

File path:	WNHS.HAEM.TetanusImmunoglobulinVFIntravenous		
Keywords:	Blood Transfusion, Blood products, plasma derived blood products. Blood bank, transfusion medicine unit, blood bank scientist, Tetanus immunoglobulin intravenous, intravenous tetanus immunoglobulin, tetanus immunoglobulin		
Document owner:	Chair of KEMH Hospital Transfusion Committee		
Author / Reviewer:	Consultant Haematologist, Scientist in Charge Transfusion Medicine, KEMH Transfusion Coordinator		
Date first issued:	01 01 2005		
Last reviewed:	01 12 2015	Next review date:	01 02 2020
Endorsed by:	KEMH Hospital Transfusion Committee	Date:	01 02 2017
Standards Applicable:	NSQHS Standards: 1 Governance, 5 Patient ID/Procedure Matching, 7 Blood Products		
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from the WNHS website.			